SUBSCRIBE
SUBSCRIBE
News   Policy

FDA Grants Priority Review To GlaxoSmithKline’s Tykerb

November 17, 2006 | 
1 min read
Nov. 16 (Bloomberg) -- GlaxoSmithKline Plc said the U.S. Food and Drug Administration gave fast-track status to its application for the experimental drug Tykerb for breast cancer, the most common cancer among women.

>>> Discuss This Story

Regulatory Europe
GlaxoSmithKline Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Megaphone with stethoscope isolated on orange background. 3d illustration
Women’s health
Biotech Leaders, Investors Ask FDA to Maintain Access to Mifepristone
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac
Collage of gavel, safety cones and roadblock
Legal
Court Suspends Mass Layoffs at HHS, Rules Staff Cuts Likely Unlawful
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Government
RFK Jr. Eyes Changes to Vaccine Injury Compensation Program
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac
Yellow warning sign symbol or alert safety danger caution illustration icon security message and exclamation triangle information icon on attention traffic background with secure alarm. 3D render.
Regulatory
FDA Mulls ‘Regulatory Action’ on Argenx’s Vyvgart Hytrulo Over Severe Safety Concerns
July 2, 2025
 · 
2 min read
 · 
Tristan Manalac